Abstract:519 Background: MicroRNA (miRNA) are short noncoding RNAs involved in regulation of gene expression and have shown promise as novel biomarkers in the diagnosis and management of testicular germ cell tumors (GCT). We report the accuracy of our combined miRNA assay in men with Clinical Stage I (CSI) GCTs. We also sought to explore the relationship between miRNA levels and patient and oncologic variables to better understand how these factors may influence miRNA results. Methods: We retrospectively identified patients at Memorial Sloan Kettering (MSK) with a newly identified testicular mass concerning for GCT who were planned for radical or partial orchiectomy and had pre-orchiectomy MSK miRNA Assay (miRNA-371a-3p and miRNA-372-3p, collectively MMA) drawn. All patients had clinically localized disease based on initial staging imaging and normalized traditional serum tumor markers (STM) post-orchiectomy. Specific miRNA levels were determined using stem-loop RT-qPCR (quantitative reverse transcription PCR), as described previously. Patient and disease factors were abstracted from the medical record. Outcomes of interest were sensitivity, specificity, PPV and NPV of MMA, and area under the receiver operating characteristic curve (AUC) of miRNA-371a-3p and 372-3p levels, calculated relative to detection of viable GCT at orchiectomy. We explored the relationship between pre-orchiectomy miRNA-371a-3p and 372-3p levels and various patient and pathologic factors using Spearman correlation and Wilcoxon rank-sum test. Results: Forty-eight patients were included in this study, 39 of whom had viable GCT at orchiectomy and 9 with no cancer or non-GCTs. Thirty-seven patients with GCT had positive pre-orchiectomy MMA results (sensitivity 94.9%, 95% CI: 88-100), while 1 of 9 patients (Leydig cell tumor) without viable GCT had a positive MMA result (specificity 88.9%, 95% CI: 68.4-100). MMA PPV was 97.4% (95% CI: 92.3-100) and NPV was 80% (95% CI: 55.2-100). AUC of miRNA-371a-3p and miRNA-372-3p was 96% (95% CI: 91.0-100) and 92% (95% CI: 84.2-99.9), respectively. Pre-orchiectomy miRNA-371a-3p and miRNA-372-3p levels were positively correlated with tumor size (Spearman coefficient ρ=0.64, 0.63, respectively; p<0.001), and with serum HCG (ρ=0.55, 0.56; p<0.001) and LDH (ρ=0.46, 0.46; p<0.001), but not AFP (ρ=0.19, 0.17; p=0.20, 0.24). Pre-orchiectomy MMA was not associated with other tested pathologic or patient characteristics including age, BMI, renal function, liver function and andrology labs. Conclusions: miRNA 371a-3p and 372-3p are highly sensitive and specific for presence of viable GCT in patients with clinically localized disease. Tumor size was the only studied pathologic factor or patient characteristic correlated with MMA levels.

MicroRNA for Prediction of Teratoma and Viable Germ Cell Tumor after Chemotherapy

Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection

Circulating MiR-125b As a Marker Predicting Chemoresistance in Breast Cancer

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management

Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis.

Plasma Micrornas Predict Chemoresistance in Patients with Metastatic Breast Cancer.

High Expression of Mir-363 Predicts Poor Prognosis and Guides Treatment Selection in Acute Myeloid Leukemia

Evaluation of Plasma Microrna Levels to Predict Insensitivity of Patients with Advanced Lung Adenocarcinomas to Pemetrexed and Platinum

The Value of miR-296 and miR-517c in Evaluating the Prognosis of Patients with Glioma after Radiotherapy and Chemotherapy

The microRNA of advanced colorectal cancer predict efficacy of first-line chemotherapy

Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses

Microrna-302a Sensitizes Testicular Embryonal Carcinoma Cells to Cisplatin-Induced Cell Death

MicroRNAs as Appropriate Discriminators in Non-Specific Alpha-Fetoprotein (AFP) Elevation in Testicular Germ Cell Tumor Patients

Serum-Based MicroRNA Signature Predicts Relapse and Therapeutic Outcome of Adjuvant Chemotherapy in Colorectal Cancer Patients

Serum Mirna-1 May Serve As a Promising Noninvasive Biomarker for Predicting Treatment Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

The Teratoma Challenge

Pre-orchiectomy serum miRNA-371a-3p and 372-3p levels in men with clinically localized testicular masses.

MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer

Tumor Mir-125B Predicts Recurrence and Survival of Patients with Clear-Cell Renal Cell Carcinoma after Surgical Resection

A Two-Microrna-based Signature Predicts First-Line Chemotherapy Outcomes in Advanced Colorectal Cancer Patients